AccessibilityHelpAbout Us
Dimerix logo

Dimerix(ASX) DXB

Market CapA$150.10MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2015)+34%
5 Year-17%
1 Year-47%
1 Month-14%
A$0.25
+0.00%
+0.00Today
Dimerix last closing stock price
MetricPriceDate
Last closeAUD 0.252026-09-11
Dimerix stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week-12.28%AUD 0.292026-09-04
1 month-13.79%AUD 0.292026-08-12
3 month+51.52%AUD 0.172026-06-12
Year to date-54.55%AUD 0.552025-12-31
1 year-46.81%AUD 0.472025-09-11
3 year+309.84%AUD 0.062023-09-12
5 year-16.67%AUD 0.302021-09-10
Since inception+33.58%AUD 0.192015-07-06

Dimerix Financials at a Glance

Market Cap

A$150.10MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

A$9.94M

Net Income (TTM)

-A$43.06M

EPS (TTM)

-A$0.05

P/E Ratio

-5.03

Dividend

A$0.00

Beta (Volatility)

0.09 (Low)

Price

A$0.25

Volume

810,805

Open

A$0.25

Previous Close

A$0.25

Daily Range

A$0.25 - A$0.26

52-Week Range

A$0.16 - A$0.67

Estimated Earnings Date

Mar 1, 2027

DXB News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Dimerix

Dimerix Limited is an Australian biopharmaceutical firm focused on developing innovative pharmaceutical solutions for medical conditions with inadequate existing treatments. The company is advancing its lead therapeutic candidate, DMX-200, through extensive clinical trials targeting respiratory complications from COVID-19 and focal segmental glomerulosclerosis (FSGS).

Products and Services
  • DMX-200 for respiratory complications related to COVID-19
  • DMX-200 for focal segmental glomerulosclerosis (FSGS)
  • DMX-700 for chronic obstructive pulmonary disease (COPD)
Growth Outlook
  • DMX-200 is in two Phase 3 trials, indicating strong clinical validation
  • Expansion into diabetic kidney disease treatment enhances market potential
  • Advancements in DMX-700 could diversify therapeutic offerings
Financial Highlights
  • Recent quarterly revenue of AUD 2.12 million, showing growth potential
  • Cash and cash equivalents of AUD 38.49 million, providing operational stability
  • Current ratio of 3.15, indicating strong liquidity position
Dimerix Limited is positioned in the biotechnology sector, focusing on unmet medical needs. The ongoing clinical trials for DMX-200 and the development of DMX-700 highlight the company's commitment to innovation. The financial metrics indicate a solid cash position, which supports ongoing research and development efforts. The company's strategic focus on expanding its product pipeline could lead to significant growth opportunities in the biopharmaceutical market.
AI Generated • Aug 21, 2026

Industry

Biotechnology

Sector

Health Care

CEO

Nina Webster, PhD, EMBA

Website

www.dimerix.com

Headquarters

Fitzroy, VIC 3065, AU

DXB Financials

Key Financial Metrics (TTM)

Gross Margin

0.00%

Operating Margin

-854.60%

Net Income Margin

-685.32%

Return on Equity

362.74%

Return on Capital

N/A

Return on Assets

-50.88%

Earnings Yield

-19.88%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

A$150.10MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

600.40M

Volume

810.80K

Avg. Volume

2.15M

Financials (TTM)

Gross Profit

A$5.59M

Operating Income

-A$69.19M

EBITDA

-A$68.85M

Operating Cash Flow

-A$12.76M

Capital Expenditure

-A$25.99K

Free Cash Flow

-A$12.78M

Cash & ST Invst.

A$16.15M

Total Debt

A$232.09K

Dimerix Performance Analysis

Dimerix annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20232023-06-30AUD 0N/A
20242024-06-30AUD 407,466N/A
20252025-06-30AUD 5,586,8281271.1%
20262026-06-30AUD 4,350,305-22.1%
Dimerix sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22024-12-31-36.2%
Q42025-06-301743.6%
Q22025-12-31-60.1%
Q42026-06-305.5%
Dimerix annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20232023-06-30AUD -0.0421.1%
20242024-06-30AUD -0.04-11.1%
20252025-06-30AUD -0.02-37.4%
20262026-06-30AUD -0.05110.6%
Dimerix sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22024-12-31-12.0%
Q42025-06-3097.4%
Q22025-12-31-4333.3%
Q42026-06-3013.2%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q4 2026YOY CHG

Revenue

A$2.23M

+395.9%

Gross Profit

A$0.00

-100.0%

Gross Margin

0.00%

N/A

Market Cap

A$150.10MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

A$10.01M

N/A

Employees

15

N/A

Net Income

-A$13.85M

-33.1%

EBITDA

-A$15.45M

-49.1%

Quarterly Fundamentals

Name
Q4 2026YOY CHG

Total Cash

A$16.15M

-27.0%

Total Debt

A$232.09K

+55.1%

Accounts Receivable

A$18.63M

+95.8%

Inventory

A$0.00

N/A

Long Term Debt

A$108.00K

+55.4%

Short Term Debt

A$124.09K

+54.8%

Return on Assets

-50.88%

N/A

Return on Invested Capital

-75.24%

N/A

Free Cash Flow

-A$21.95M

-32.7%

Operating Cash Flow

-A$21.95M

-32.8%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
NYR.AXNyrada Inc.
A$0.71-1.39%
ARX.AXAroa Biosurgery Limited
A$0.55+2.80%
OCC.AXOrthocell Limited
A$0.71-2.07%
IMM.AXImmutep Limited
A$0.06+27.27%

Trending Stocks

Symbol / CompanyPricePrice Chg
KHCKraft Heinz
$24.60+0.01%
ACVAACV Auctions
$10.41+0.44%
TNONTenon Medical
$5.93+0.12%
ETHAiShares Ethereum Trust - iShares Ethereum Trust ETF
$19.16+0.03%

Questions About DXB

What is the current price of Dimerix?

Dimerix is trading at A$0.25 per share.

What is the 52-week range for Dimerix?

Over the past 52 weeks, Dimerix has traded between A$0.16 and A$0.67.

How much debt does Dimerix have?

As of the most recent reporting period, Dimerix reported total debt of A$232.09K.

How much cash does Dimerix have on hand?

Dimerix reported A$16.15M in cash and cash equivalents in its most recent financial results.

What is Dimerix’s dividend yield?

Dimerix does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services